本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Sarepta Therapeutics

54.01
-0.4100-0.75%
成交量:26.87萬
成交額:1,451.33萬
市值:52.41億
市盈率:23.10
高:55.01
開:54.59
低:53.37
收:54.42
資料載入中...
2025/03/12

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/02/28

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/27

重要事件披露

Form 8-K - Current report
2025/02/14

重要事件披露

Form 8-K - Current report
2025/01/13

重要事件披露

Form 8-K - Current report
2024/12/12

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/12/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/26

重要事件披露

Form 8-K - Current report
2024/11/13

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/06

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

重要事件披露

Form 8-K - Current report
2024/08/30

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/07

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/25

關聯方擬減持公告

Form144|賽普拉高管Bilal Arif擬減持3898股,總價約63.9萬美元
2024/06/25

關聯方擬減持公告

Form144|賽普拉高管Ryan Brown擬減持38957股,總價約638萬美元
2024/06/24

關聯方擬減持公告

Form144|賽普拉高管Bilal Arif擬減持7859股,總價約126萬美元
2024/06/07

重要事件披露

Form 8-K - Current report
2024/05/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/03/28

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments